What Diclofenac-ratiopharm retard Treats: Main Uses and Benefits

This medication is used to relieve a combination of symptoms related to inflammatory or irritative states in the body, specifically pain, swelling, and inflammation. The medication is generally applied across conditions where symptoms may intensify temporarily, such as conditions involving inflammatory or irritative processes.

This medication may be considered relevant for easing symptoms that require continued support, applied across domains where additional symptomatic support is needed. This may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress.

Supporting Comfort in Painful and Inflammatory Conditions

This medication is generally applied during phases of increased distress or discomfort, contributing to easing the overall symptom load. It is considered relevant for managing symptom clusters in conditions involving joints, the spine, and soft tissues, such as rheumatoid arthritis, osteoarthritis, backaches, gout attacks, and pain following sprains or surgery.

It is often used when symptoms intensify and short-term symptomatic assistance is needed. This provides support that helps ease the overall symptom burden when symptoms escalate temporarily.

---

Quick Fact: Relief for Symptom Clusters

Diclofenac-ratiopharm retard is considered relevant for managing groups of symptoms that often appear together, such as the combination of pain, stiffness, and swelling.

Diclofenac-ratiopharm retard (a type of Non-Steroidal Anti-Inflammatory Drug, or NSAID) is generally used to treat pain and inflammation. However, it is not suitable for everyone. Your doctor must carefully assess your medical history before prescribing it, especially considering its prolonged-release formulation.

Contraindications (Who Should Not Use It)

This medication is strictly contraindicated if you have:

• A known allergy or hypersensitivity to diclofenac, aspirin, or any other NSAID, particularly if it has caused asthma, urticaria (hives), or acute rhinitis.
• An active stomach or intestinal ulcer, bleeding, or perforation, or a history of recurrent issues.
• A history of gastrointestinal bleeding or perforation related to prior NSAID treatment.
• Established severe heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• Severe kidney or liver impairment.
• Are in the last trimester of pregnancy.

Caution and Special Consideration (Who Needs Careful Monitoring)

Particular caution is required for the elderly, patients with mild to moderate heart failure (NYHA Class I), those with risk factors for cardiovascular disease (e.g., high blood pressure, diabetes, high cholesterol, smoking), or a history of gastrointestinal disorders such as Crohn's disease or ulcerative colitis. The lowest effective dose for the shortest duration should be used.

Interactions with other medicines and products

Official regulatory information describes two primary types of clinically significant interaction patterns for diclofenac sodium: combinations that increase the risk of toxicity and combinations that alter drug concentrations.

Contraindicated and High-Risk Combinations:

Interaction Type	Interacting Agent Category	Restriction / Outcome
Additive Risk	Other Systemic NSAIDs (Non-steroidal Anti-inflammatory Drugs), including selective COX-2 inhibitors and Aspirin (Acetylsalicylic acid)	Contraindicated due to heightened risk of serious gastrointestinal bleeding and ulceration.
Additive Risk	Anticoagulants, Anti-platelet agents, SSRIs, and Systemic Corticosteroids	Documented increased risk of severe bleeding, particularly gastrointestinal, upon co-administration.

Pharmacokinetic and Exposure Alterations:

Interaction Type	Interacting Agent	Outcome Documented by Regulators
Metabolic/Exposure	CYP2C9 Inhibitors (e.g., Voriconazole, Sulfinpyrazone)	Can significantly increase the systemic exposure (AUC and Cmax) of diclofenac.
Renal Clearance	Lithium, Methotrexate, Digoxin	Diclofenac may increase the plasma concentration of these co-administered drugs by reducing their renal clearance.
Impaired Effect	Diuretics and certain Antihypertensives	Diclofenac may officially impair the effectiveness of these agents and increase the risk of renal function deterioration.

Substance-Related and Population-Specific Notes:

Co-consumption of Alcohol is documented to increase the likelihood of serious gastrointestinal adverse events. Regulatory labels also specify that Elderly Patients are at a greater risk for the serious gastrointestinal adverse events associated with these documented drug interactions.

Diclofenac-ratiopharm retard primarily acts by directly and competitively inhibiting Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular action immediately suppresses the production of various prostanoids, such as PGE2, which are key chemical mediators in the body.

The suppression of COX activity modulates the entire Prostaglandin Cascade, a critical pathway associated with heightened physiological responses. By limiting the availability of these mediators, the mechanism dampens local vasodilation and results in reduced local inflammation and decreased sensitization of nociceptive fibers at the site of action.

While the anti-inflammatory action is predominantly peripheral, the drug also contributes to central modulation by inhibiting PGE2 synthesis in the hypothalamus. This systemic activity alters hypothalamic set-point regulation, causing a reduction in elevated body temperature when a febrile state is present (antipyresis).

The 'retard' (sustained-release) feature ensures a gradual and prolonged absorption into the systemic circulation. This formulation design maintains a steady concentration of the active ingredient, enabling continuous enzyme inhibition and sustained pathway modulation across the dosage interval.

The administration of Diclofenac-ratiopharm retard (prolonged-release tablets) follows specific protocols to ensure proper drug delivery and consistent use.

---

Official Administration Protocol

The route of administration for this specific formulation is oral, achieved by swallowing the tablet.

Usage Component	Official Labeled Instruction
Standard Adult Dose & Frequency	The standard regimen is typically 100 mg taken once daily (OD). The total daily dosage should generally not exceed 150 mg.
Preparation & Intake	The prolonged-release tablet must be swallowed whole with liquid and must not be crushed, chewed, or divided, as this disrupts the controlled-release system. Intake is advised with or immediately after food to aid tolerability.
Dosing Constraint	The retard formulation is not suitable for use in situations requiring a rapid onset of effect, due to its modified-release kinetic profile.
Missed Dose Rule	If a scheduled dose is missed, the protocol is to skip the forgotten dose and resume the normal regimen with the next scheduled intake; a double dose should not be taken.

---

Population Use and Duration Principles

The 100 mg prolonged-release tablet is not suitable for administration to children or adolescents. For older adults, while no specific dosage adjustment is universally required, the principle of using the lowest effective dose is emphasized. Treatment follows the overarching principle of using the lowest effective dose for the shortest duration necessary for symptomatic management.

Research Evidence / Overview of Studies for Diclofenac-ratiopharm retard

Evidence for Use in Chronic Joint Conditions

This section summarizes the structure of the clinical research—primarily Randomized Controlled Trials (RCTs) and meta-analyses—that was evaluated in chronic conditions marked by functional limitations, such as Osteoarthritis and Rheumatoid Arthritis. These studies examined how symptoms change over time when this medication was observed in adult patient populations.

Studies Examining Osteoarthritis (OA)

Research for Osteoarthritis (OA) primarily involved short-term RCTs and systematic reviews. The outcomes monitored were mainly patient-reported outcomes describing perceived discomfort, specifically changes in pain intensity and outcomes reflecting daily functioning or activity level.

Findings describe patterns observed in the studies related to physical discomfort and functional metrics. However, the core controlled studies are typically short-term, meaning that long-term effects are not fully established and follow-up durations were limited. Data for certain groups, such as those with pre-existing risk factors, often relies on post-marketing studies and may remain insufficient for detailed certainty.

Studies Examining Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)

For Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), research relied on RCTs and comprehensive systematic reviews. These studies monitored outcomes linked to inflammatory or irritative states, including changes in the duration of morning stiffness, measures of pain, and overall evaluations of systemic or functional imbalance.

Research Base for Acute Pain and Temporary Symptom Relief

The evidence for acute pain relies on short-term, placebo-controlled trials. These studies focused on adults experiencing conditions associated with acute or disruptive episodes, such as pain following procedures or injuries. Studies monitored outcomes describing episodic or acute changes, including the time to onset and the duration of observed changes in pain intensity.

Evidence in Specific Patient Groups

The primary research for Diclofenac was evaluated in a broad population of symptomatic adults across the core indications. Studies involving adults with comorbidities or those considered high-risk generally exist in the form of post-marketing observational research. Research for the use of this medication in children remains very limited in the core evidence base. Furthermore, the results apply only to the populations studied, and subgroup findings concerning older adults or those with multiple underlying health conditions are often uncertain.

Key Studies & References

1. Efficacy of ultramicronised diclofenac in patients with osteoarthritis – systematic review with network meta-analysis
2. Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Common questions about Diclofenac-ratiopharm retard (FAQ)

Q: What is Diclofenac-ratiopharm retard and what is it used for?

A: Diclofenac-ratiopharm retard contains the active substance diclofenac sodium, which belongs to a group of medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). NSAIDs are used to reduce pain and inflammation.

Diclofenac-ratiopharm retard is used to treat:

• Acute painful inflammatory conditions such as arthritis (inflammation of the joints).
• Chronic forms of rheumatoid arthritis (a long-term condition that causes pain, swelling, and stiffness in the joints).
• Arthrosis (degenerative joint disease) and spondyloarthritides (inflammatory arthritis affecting the spine).

It is formulated as a "retard" (sustained-release) tablet, which means the active ingredient is released slowly over a longer period.

Q: How long does Diclofenac-ratiopharm retard take to work?

A: As a sustained-release (retard) formulation, the release of the active ingredient, diclofenac, is gradual. Patients usually begin to feel a reduction in pain and inflammation within a few hours of the first dose. However, the full therapeutic benefit for chronic conditions like rheumatoid arthritis may take several days to a few weeks of consistent use to be fully realized, as the medicine works to reduce underlying inflammation.

Q: Can Diclofenac-ratiopharm retard be taken with food?

A: Yes, Diclofenac-ratiopharm retard tablets should be swallowed whole with a glass of water during or after a meal. Taking the medicine with food can help minimize the risk of stomach irritation. The tablets should not be chewed or crushed because this would destroy the special sustained-release coating.

Q: What should I do if I miss a dose of Diclofenac-ratiopharm retard?

A: If you forget to take a dose, do not take a double dose to make up for the forgotten tablet. Instead, skip the missed dose and take your next dose at the usual time. If you miss multiple doses, or are concerned, you should consult a healthcare professional.

Q: What are the common side effects of Diclofenac-ratiopharm retard?

A: Like all medicines, Diclofenac-ratiopharm retard can cause side effects, although not everybody gets them. Common side effects (may affect up to 1 in 10 people) generally involve the gastrointestinal tract and include:

• Nausea, vomiting
• Diarrhoea, constipation
• Stomach pain, indigestion
• Loss of appetite
• Headache, dizziness

Serious side effects can include stomach bleeding or ulcers, and signs of an allergic reaction (like rash or difficulty breathing). If you experience any severe side effects, stop taking the medicine and seek immediate medical attention.

Q: Can Diclofenac-ratiopharm retard be used during pregnancy or while breastfeeding?

A: The use of Diclofenac-ratiopharm retard is not recommended during the first six months of pregnancy. It must not be taken during the last three months of pregnancy as it may harm the unborn child or cause problems during delivery.

Diclofenac passes into breast milk in small amounts. To avoid potential risks to the infant, it is generally recommended to avoid using Diclofenac-ratiopharm retard while breastfeeding. You should always discuss the risks and benefits with your doctor before using this medicine during pregnancy or while breastfeeding.

Q: Can I take other painkillers while taking Diclofenac-ratiopharm retard?

A: You should not take other NSAIDs (such as ibuprofen, naproxen, or aspirin for pain) at the same time as Diclofenac-ratiopharm retard. Taking multiple NSAIDs significantly increases the risk of serious side effects, particularly stomach bleeding or ulcers.

However, some other types of pain relievers, such as paracetamol (acetaminophen), may be taken, but you should always consult your doctor or pharmacist before combining any painkillers to ensure safety and avoid potential interactions.

Storage

To ensure the stability and efficacy of Diclofenac-ratiopharm retard, it should be stored correctly. Generally, the tablets should be kept at room temperature, specifically below 25°C (77°F). It is crucial to keep the medication in its original packaging and protect it from moisture and direct light. Always store the drug out of the sight and reach of children.

Disposal

Do not dispose of Diclofenac-ratiopharm retard through household waste or wastewater, as this can pose risks to the environment. When the medication is no longer needed or has expired, consult your pharmacist or local waste disposal service for guidance on proper drug take-back or disposal programs. These services ensure the safe and environmentally responsible elimination of unused medicines, preventing accidental ingestion and minimizing environmental contamination.